U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission

MedGen UID:
57572
•Concept ID:
C0153888
•
Neoplastic Process
Synonyms: Chronic Granulocytic Leukemia in Remission; Chronic Myelocytic Leukemia in Remission; Chronic Myelogenous Leukemia in Remission; Chronic Myeloid Leukemia (in Remission); Chronic myeloid leukemia in remission; Chronic Myeloid Leukemia in Remission; CML in Remission
SNOMED CT: Chronic myeloid leukemia in remission (92817004)

Definition

A finding of chronic myelogenous leukemia, BCR-ABL1 positive that is not growing and responds to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVChronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission

Professional guidelines

PubMed

Management of chronic myeloid leukemia in 2023 - common ground and common sense.
Senapati J, Sasaki K, Issa GC, Lipton JH, Radich JP, Jabbour E, Kantarjian HM
Blood Cancer J 2023 Apr 24;13(1):58. doi: 10.1038/s41408-023-00823-9. PMID: 37088793Free PMC Article
Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities.
Narlı Özdemir Z, Kılıçaslan NA, Yılmaz M, Eşkazan AE
Int J Hematol 2023 Jan;117(1):3-15. Epub 2022 Sep 5 doi: 10.1007/s12185-022-03446-1. PMID: 36064839
Management of Chronic Myeloid Leukemia in Children and Young Adults.
Ford M, Mauro M, Aftandilian C, Sakamoto KM, Hijiya N
Curr Hematol Malig Rep 2022 Oct;17(5):121-126. Epub 2022 Aug 3 doi: 10.1007/s11899-022-00673-5. PMID: 35920965Free PMC Article

Recent clinical studies

Therapy

Chronic Myeloid Leukemia in Children and Adolescents.
Gotesman M, Raheel S, Panosyan EH
Adv Pediatr 2023 Aug;70(1):145-155. Epub 2023 May 12 doi: 10.1016/j.yapd.2023.04.002. PMID: 37422292
Management of chronic myeloid leukemia in 2023 - common ground and common sense.
Senapati J, Sasaki K, Issa GC, Lipton JH, Radich JP, Jabbour E, Kantarjian HM
Blood Cancer J 2023 Apr 24;13(1):58. doi: 10.1038/s41408-023-00823-9. PMID: 37088793Free PMC Article
Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions.
Osman AEG, Deininger MW
Blood Rev 2021 Sep;49:100825. Epub 2021 Mar 16 doi: 10.1016/j.blre.2021.100825. PMID: 33773846Free PMC Article
Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review.
Patnaik MM, Lasho T
Hematology Am Soc Hematol Educ Program 2020 Dec 4;2020(1):460-464. doi: 10.1182/hematology.2020000163. PMID: 33275673Free PMC Article
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.
Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen JJWM, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Mayer J, Nicolini F, Niederwieser D, Pane F, Radich JP, Rea D, Richter J, Rosti G, Rousselot P, Saglio G, Saußele S, Soverini S, Steegmann JL, Turkina A, Zaritskey A, Hehlmann R
Leukemia 2020 Apr;34(4):966-984. Epub 2020 Mar 3 doi: 10.1038/s41375-020-0776-2. PMID: 32127639Free PMC Article

Prognosis

Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights.
Iezza M, Cortesi S, Ottaviani E, Mancini M, Venturi C, Monaldi C, De Santis S, Testoni N, Soverini S, Rosti G, Cavo M, Castagnetti F
Cells 2023 Jun 23;12(13) doi: 10.3390/cells12131703. PMID: 37443737Free PMC Article
Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease.
Zuna J, Hovorkova L, Krotka J, Koehrmann A, Bardini M, Winkowska L, Fronkova E, Alten J, Koehler R, Eckert C, Brizzolara L, Trkova M, Stuchly J, Zimmermann M, De Lorenzo P, Valsecchi MG, Conter V, Stary J, Schrappe M, Biondi A, Trka J, Zaliova M, Cazzaniga G, Cario G
Leukemia 2022 Dec;36(12):2793-2801. Epub 2022 Aug 6 doi: 10.1038/s41375-022-01668-0. PMID: 35933523
Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions.
Osman AEG, Deininger MW
Blood Rev 2021 Sep;49:100825. Epub 2021 Mar 16 doi: 10.1016/j.blre.2021.100825. PMID: 33773846Free PMC Article
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.
Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Boquimpani C, Pasquini R, Clark RE, Dubruille V, Flinn IW, Kyrcz-Krzemien S, Medras E, Zanichelli M, Bendit I, Cacciatore S, Titorenko K, Aimone P, Saglio G, Hochhaus A
Leukemia 2021 Feb;35(2):440-453. Epub 2021 Jan 7 doi: 10.1038/s41375-020-01111-2. PMID: 33414482Free PMC Article
Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review.
Patnaik MM, Lasho T
Hematology Am Soc Hematol Educ Program 2020 Dec 4;2020(1):460-464. doi: 10.1182/hematology.2020000163. PMID: 33275673Free PMC Article

Clinical prediction guides

Exploration of treatment-free remission in CML, based on molecular monitoring.
Zhang Z, Zhou X, Zhou X, Cheng Z, Hu Y
Cancer Med 2024 Jan;13(1):e6849. Epub 2023 Dec 22 doi: 10.1002/cam4.6849. PMID: 38133525Free PMC Article
Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights.
Iezza M, Cortesi S, Ottaviani E, Mancini M, Venturi C, Monaldi C, De Santis S, Testoni N, Soverini S, Rosti G, Cavo M, Castagnetti F
Cells 2023 Jun 23;12(13) doi: 10.3390/cells12131703. PMID: 37443737Free PMC Article
Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease.
Zuna J, Hovorkova L, Krotka J, Koehrmann A, Bardini M, Winkowska L, Fronkova E, Alten J, Koehler R, Eckert C, Brizzolara L, Trkova M, Stuchly J, Zimmermann M, De Lorenzo P, Valsecchi MG, Conter V, Stary J, Schrappe M, Biondi A, Trka J, Zaliova M, Cazzaniga G, Cario G
Leukemia 2022 Dec;36(12):2793-2801. Epub 2022 Aug 6 doi: 10.1038/s41375-022-01668-0. PMID: 35933523
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.
Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen JJWM, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Mayer J, Nicolini F, Niederwieser D, Pane F, Radich JP, Rea D, Richter J, Rosti G, Rousselot P, Saglio G, Saußele S, Soverini S, Steegmann JL, Turkina A, Zaritskey A, Hehlmann R
Leukemia 2020 Apr;34(4):966-984. Epub 2020 Mar 3 doi: 10.1038/s41375-020-0776-2. PMID: 32127639Free PMC Article
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL
N Engl J Med 2001 Apr 5;344(14):1031-7. doi: 10.1056/NEJM200104053441401. PMID: 11287972

Recent systematic reviews

Does presence of complex translocations involving BCR::ABL1 in chronic myeloid leukemia affect the response rate to tyrosine kinase inhibitors? A systematic review of the literature.
Sharma D, Wilson C, Kumar S, Ghose S, Sahoo R, Sharawat SK
Ann Diagn Pathol 2024 Aug;71:152303. Epub 2024 Apr 9 doi: 10.1016/j.anndiagpath.2024.152303. PMID: 38636337
A Systematic Review on Second Treatment-Free Remission (TFR) Attempt in Chronic Myeloid Leukemia (CML): Can it be Applied in Clinical Practice?
Çiftçiler R, Akın MG, Erat Z, Eşkazan AE
Clin Lymphoma Myeloma Leuk 2023 Jan;23(1):8-14. Epub 2022 Oct 5 doi: 10.1016/j.clml.2022.09.004. PMID: 36344420
The prognostic importance of BCR-ABL transcripts in Chronic Myeloid Leukemia: A systematic review and meta-analysis.
Ghalesardi OK, Khosravi A, Azizi E, Ahmadi SE, Hajifathali A, Bonakchi H, Shahidi M
Leuk Res 2021 Feb;101:106512. Epub 2021 Jan 19 doi: 10.1016/j.leukres.2021.106512. PMID: 33524640
Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis.
Campiotti L, Suter MB, Guasti L, Piazza R, Gambacorti-Passerini C, Grandi AM, Squizzato A
Eur J Cancer 2017 May;77:48-56. Epub 2017 Mar 30 doi: 10.1016/j.ejca.2017.02.028. PMID: 28365527
Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia.
Hoffmann VS, Hasford J, Deininger M, Cortes J, Baccarani M, Hehlmann R
J Cancer Res Clin Oncol 2017 Jul;143(7):1311-1318. Epub 2017 Mar 8 doi: 10.1007/s00432-017-2385-7. PMID: 28275866

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...